The Role of Pregabalin in Relieving Ureteral Stent-related Symptoms: a Randomized Controlled Clinical Trial

Overview

Journal Int Urol Nephrol

Publisher Springer

Specialty Nephrology

Date 2017 Mar 6

PMID 28260223

Citations 10

Authors

Maged Ragab

Mohamed G Soliman

Ahmed Tawfik

Ali Abdel Raheem

Hassan El-Tatawy

Mohamed Abo Farha

Michael Magdy

Osama Elashry

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the role of pregabalin in relieving USRS in patients with an indwelling double-J (DJ) stents.

Patients And Methods: A total of 500 adult patients with a unilateral single ureteral stone who underwent ureteroscopic stone management and required DJ stent insertion were prospectively included in our study. Patients were blindly assigned into four groups A, B, C and D. Those in group A were managed with combination of solifenacin 5-mg tablets and pregabalin 75-mg capsules bid. Patients in group B were managed with solifenacin 5-mg tablets. Those in group C were managed with pregabalin 75-mg capsules bid. Those in group D were control group. All patients were evaluated on day 15 postoperatively for stent-related symptoms using the Arabic translated and validated ureteral stent symptom questionnaire (USSQ).

Results: The total USSQ score as well as general health index was significantly lower in group A as compared to other groups. In addition, urinary symptom index was significantly improved in both groups A and B as compared to group C and group D. Pain symptom index was significantly improved in both groups A and C as compared to groups B and D. No statistically significant difference was reported regarding sexual index and work performance index among the whole study groups.

Conclusion: Pregabalin appears to be a well-tolerated, safe and effective drug in reducing most of USRS, especially relief of pain with subsequent improvement of patient's quality of life. Its combination with solifenacin should be considered to manage patients with USRS as it shows a significant improvement in total USSQ score and general health index when compared to each drug alone.

Citing Articles

The Beneficial Effects of Alpha-Blockers, Antimuscarinics, Beta 3-Agonist, and PDE5-Inhibitors for Ureteral Stent-Related Discomfort: A Systematic Review and Meta-Analysis from KSER Update Series.

Moon Y, Chung D, Kim D, Jung H, Jeon S, Kang S Medicina (Kaunas). 2025; 61(2).

PMID: 40005349 PMC: 11857426. DOI: 10.3390/medicina61020232.

Pharmacological treatment of bladder stent symptoms.

Piedad J, Allam M, Mahmalji W Bladder (San Franc). 2024; 11(3):e21200012.

PMID: 39640188 PMC: 11617032. DOI: 10.14440/bladder.2024.0018.

A critical review on the role of perioperative pregabalin in ureteroscopy for urolithiasis.

Stern K, Narang G, Wymer K Transl Androl Urol. 2024; 13(6):1064-1066.

PMID: 38983465 PMC: 11228671. DOI: 10.21037/tau-24-39.

Comparing efficacy and safety of mirabegron, tamsulosin, and solifenacin in ureteral stent-related symptoms: outcomes from a network meta-analysis.

Xiang N, Hu Y, Peng W, Luo M, Yang Y, Zhang Q Transl Androl Urol. 2024; 13(5):699-707.

PMID: 38855609 PMC: 11157398. DOI: 10.21037/tau-23-642.

Is dismissing preoperative pregabalin premature?-the role of gabapentinoids in multimodal pain management following ureteroscopic stone surgery.

Qi R, Koo K Transl Androl Urol. 2024; 13(3):467-469.

PMID: 38590966 PMC: 10999028. DOI: 10.21037/tau-23-596.

References

Hansen H . Interstitial cystitis and the potential role of gabapentin. South Med J. 2000; 93(2):238-42. View

Lim K, Kim Y, Lee T, Park S . Effects of tamsulosin, solifenacin, and combination therapy for the treatment of ureteral stent related discomforts. Korean J Urol. 2011; 52(7):485-8. PMC: 3151637. DOI: 10.4111/kju.2011.52.7.485. View

Bockbrader H, Wesche D, Miller R, Chapel S, Janiczek N, Burger P . A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010; 49(10):661-9. DOI: 10.2165/11536200-000000000-00000. View

Jeong H, Kwak C, Lee S . Ureteric stenting after ureteroscopy for ureteric stones: a prospective randomized study assessing symptoms and complications. BJU Int. 2004; 93(7):1032-4. DOI: 10.1111/j.1464-410X.2004.4776a.x. View

Park S, Jung S, Lee J, Rim J . The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms. J Endourol. 2009; 23(11):1913-7. DOI: 10.1089/end.2009.0173. View

Carbone A, Antonio C, Palleschi G, Giovanni P, Conte A, Bova G . Gabapentin treatment of neurogenic overactive bladder. Clin Neuropharmacol. 2006; 29(4):206-14. DOI: 10.1097/01.WNF.0000228174.08885.AB. View

Ho C, Chen S, Chung S, Lee Y, Chen J, Yu H . Determining the appropriate length of a double-pigtail ureteral stent by both stent configurations and related symptoms. J Endourol. 2008; 22(7):1427-31. DOI: 10.1089/end.2008.0037. View

Yoshimura N, Chancellor M . Current and future pharmacological treatment for overactive bladder. J Urol. 2002; 168(5):1897-913. DOI: 10.1016/S0022-5347(05)64261-9. View

Pollard S, Macfarlane R . Symptoms arising from Double-J ureteral stents. J Urol. 1988; 139(1):37-8. DOI: 10.1016/s0022-5347(17)42282-8. View

10.

Ansari M, Bharti A, Kumar R, Ranjan P, Srivastava A, Kapoor R . Gabapentin: a novel drug as add-on therapy in cases of refractory overactive bladder in children. J Pediatr Urol. 2011; 9(1):17-22. DOI: 10.1016/j.jpurol.2011.10.022. View

11.

Joshi H, Newns N, Stainthorpe A, MacDonagh R, Keeley Jr F, Timoney A . Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol. 2003; 169(3):1060-4. DOI: 10.1097/01.ju.0000049198.53424.1d. View

12.

Tehranchi A, Rezaei Y, Khalkhali H, Rezaei M . Effects of terazosin and tolterodine on ureteral stent related symptoms: a double-blind placebo-controlled randomized clinical trial. Int Braz J Urol. 2014; 39(6):832-40. DOI: 10.1590/S1677-5538.IBJU.2013.06.09. View

13.

Toth C . Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. Pain Med. 2010; 11(3):456-65. DOI: 10.1111/j.1526-4637.2009.00796.x. View

14.

Chew B, Knudsen B, Denstedt J . The use of stents in contemporary urology. Curr Opin Urol. 2004; 14(2):111-5. DOI: 10.1097/00042307-200403000-00011. View

15.

Yakoubi R, Lemdani M, Monga M, Villers A, Koenig P . Is there a role for α-blockers in ureteral stent related symptoms? A systematic review and meta-analysis. J Urol. 2011; 186(3):928-34. DOI: 10.1016/j.juro.2011.04.061. View

16.

Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo I, DArmiento M . Effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study. J Endourol. 2008; 22(4):651-6. DOI: 10.1089/end.2007.0257. View

17.

El-Nahas A, Tharwat M, Elsaadany M, Mosbah A, Gaballah M . A randomized controlled trial comparing alpha blocker (tamsulosin) and anticholinergic (solifenacin) in treatment of ureteral stent-related symptoms. World J Urol. 2015; 34(7):963-8. DOI: 10.1007/s00345-015-1704-3. View

18.

Beddingfield R, Pedro R, Hinck B, Kreidberg C, Feia K, Monga M . Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study. J Urol. 2008; 181(1):170-6. DOI: 10.1016/j.juro.2008.09.026. View

19.

Kuyumcuoglu U, Eryildirim B, Tuncer M, Faydaci G, Tarhan F, Ozgul A . Effectiveness of medical treatment in overcoming the ureteral double-J stent related symptoms. Can Urol Assoc J. 2011; 6(6):E234-7. PMC: 3529727. DOI: 10.5489/cuaj.10143. View

20.

Hao P, Li W, Song C, Yan J, Song B, Li L . Clinical evaluation of double-pigtail stent in patients with upper urinary tract diseases: report of 2685 cases. J Endourol. 2008; 22(1):65-70. DOI: 10.1089/end.2007.0114. View